Inovytec Signs Deal with Global Medical Supply to Supply 1500 Portable Ventilators

January 11, 2021

Inovytec, based in Israel, has signed a deal to supply 1,500 advanced portable ventilators to Global Medical Supply, a California-based distributor that was awarded a supply agreement with the state of California.

The machines will be used to aid patients with respiratory illnesses during the current COVID-19 pandemic and beyond.

“When looking for a partner that could quickly supply us with the quality ventilators we needed, Inovytec answered the call. Its lightweight and durable ventilators give patients the flexibility needed to be transported between wards or hospitals seamlessly,” said Edward Kim, a partner at Global Medical Supply. “At the same time, Inovytec’s ventilators are affordable, meaning we could care for more patients and the lack of constant maintenance allows us to keep them in storage if need be while knowing they will be ready when needed.”

The Ventway Sparrow ventilator is designed for mobility and ease of use. It weighs only one kilogram and allows for both invasive and noninvasive ventilation. It has been chosen for COVID-19 wards in Italy, Brazil and Israel. It is currently cleared for use in the United States under FDA Emergency Use Authorization.

“We are dedicated to providing the best devices possible that will save lives,” said Udi Kantor, Co-founder and CEO of Inovytec. “Ventilators have been an invaluable resource to medical professionals in recent months and we are delighted that we have been able to aid them in their efforts to care for people with respiratory issues. Looking beyond the pandemic, our ventilators will enable paramedics and hospitals to safely and easily transfer patients, and we look forward to serving other medical facilities in California and other states in the US to provide the best equipment possible for those who need it.”

SourceInovytec

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”